---
schema_version: "secwatch.filing_event.v1"
accession: "0000010795-25-000036"
form_type: "8-K"
ticker: "BDX"
cik: "0000010795"
company_name: "BECTON DICKINSON & CO"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-22T23:41:47.982470+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BD Q2 fiscal 2025: Revenue $5.27B (+4.5%), GAAP EPS $1.07 (down 42% YoY), adj. EPS $3.35

## Summary
- Revenue increased 4.5% as reported to $5.272B; organic growth 0.9%, currency-neutral growth 6.0%.
- GAAP diluted EPS $1.07, down 42.2% YoY; adjusted diluted EPS $3.35, up 5.7% YoY.
- Company updates full-year fiscal 2025 guidance and provides estimated tariff impact; specific numbers not detailed.
- Announces intention to invest $2.5B in U.S. manufacturing capacity over next 5 years.
- Business highlights include FDA clearances for Phasix ST Umbilical Hernia Patch and advanced microbiology solution.

## SEC filing metadata
- accession: 0000010795-25-000036
- form_type: 8-K
- ticker: BDX
- cik: 0000010795
- company_name: BECTON DICKINSON & CO
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10795/000001079525000036/0000010795-25-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10795/000001079525000036/bdx-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000010795-25-000036
- JSON: https://secwatch.observer/filing/0000010795-25-000036.json
- Plain text: https://secwatch.observer/filing/0000010795-25-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.